Attached files
| file | filename |
|---|---|
| 10-K - ORE PHARMACEUTICAL HOLDINGS INC. 10-K - ORE PHARMACEUTICAL HOLDINGS INC. | a6229817.htm |
| EX-32 - EXHIBIT 32 - ORE PHARMACEUTICAL HOLDINGS INC. | a6229817ex32.htm |
| EX-21 - EXHIBIT 21 - ORE PHARMACEUTICAL HOLDINGS INC. | a6229817ex21.htm |
| EX-31.1 - EXHIBIT 31.1 - ORE PHARMACEUTICAL HOLDINGS INC. | a6229817ex31-1.htm |
| EX-31.2 - EXHIBIT 31.2 - ORE PHARMACEUTICAL HOLDINGS INC. | a6229817ex31-2.htm |
| EX-10.30 - EXHIBIT 10.30 - ORE PHARMACEUTICAL HOLDINGS INC. | a6229817ex10-30.htm |
Exhibit 23
Consent of Independent Registered Public Accounting Firm
|
(1)
|
Post-Effective Amendment No. 1 to Form S-8 Registration Statement Nos. 333-53083, 333-80931, 333-44562, 333-92080, 333-107096, and 333-127190 pertaining to the 1997 Equity Incentive Plan and the 1997 Non-Employee Directors’ Stock Option Plan of Ore Pharmaceutical Holdings Inc.
|
|
(2)
|
Form S-8 Registration Statement No. 333-163131 pertaining to the 2009 Omnibus Equity Incentive Plan of Ore Pharmaceutical Holdings Inc.
|
of our report dated March 31, 2010, with respect to the consolidated financial statements of Ore Pharmaceutical Holdings Inc. (formerly Ore Pharmaceuticals Inc.) included in its Annual Report on Form 10-K for the year ended December 31, 2009.
/s/ Ernst & Young LLP
Baltimore, Maryland
March 31, 2010